Alnylam Touts HBV IP amid Competition from Arrowhead, Tekmira | GenomeWeb

NEW YORK (GenomeWeb) – Alnylam Pharmaceuticals last week announced its control of a US patent, acquired through its purchase of Merck's RNAi drug assets earlier this year, that it says is a necessary piece of intellectual property for any group looking to develop an siRNA-based treatment for hepatitis B virus infection.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: CRISPR-based barcodes to trace cell lineages, and more.

The director of the National Institutes of Health Francis Collins sang the national anthem this week before a baseball game.

French researchers criticize unexpected government plan to cut research funding, ScienceInsider reports.

Jeremy Berg is to be the next editor in chief of Science magazine.